Vogenx initiates Phase 2b EMERGE trial of mizagliflozin for post-bariatric hypoglycemia
The company reported third-quarter 2026 results, with the trial underway and $82.1 million in cash after its August IPO.
Vogenx, Inc. reported its third quarter 2026 financial results and business update on November 6, 2026. In October 2026, the company initiated EMERGE (NCT07760961), a randomized, placebo-controlled, double-blind, parallel-group Phase 2b study evaluating mizagliflozin at 5 mg and 10 mg doses over 28 days in approximately 36 adults with post-bariatric hypoglycemia (PBH).1 The study will run at multiple centers in the United States, with topline results expected in the second half of 2027.1 The company also plans to start a Phase 2 study of mizagliflozin for gastroparesis in the first half of 2027.1
On the leadership side, Ken Toombs was appointed in September 2026 as an independent board member and chair of the audit committee.1 In October 2026, Rich Gorman joined Vogenx as Chief Commercial Officer, resigning his board seat effective October 12, 2026, and will lead commercial operations, corporate strategy and business development.1
On financing, the company completed a $93.4 million IPO in August 2026, selling 7,187,500 shares at $13.00 per share including the underwriter's full exercise of its overallotment option, for net proceeds of about $84.4 million.1 As of September 30, 2026, cash, cash equivalents and marketable securities totaled $82.1 million, up from $601 thousand at the end of 2025, reflecting the IPO proceeds.1
Vogenx's lead candidate, mizagliflozin, is being developed for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing's Syndrome.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.